10:04 AM EST - Oncolytics Biotech Inc : Announced it will host a key opinion leader webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers. The webinar will take place on Tuesday, July 22, 2025, at 1:00 p.m. ET. The webinar will feature KOLs Dirk Arnold, M.D., Ph.D. (Asklepios Tumorzentrum Hamburg), Alexander Eggermont, M.D., Ph.D. (University Medical Center Utrecht), Sanjay Goel, M.D., M.S., FASCO (Rutgers Cancer Institute of New Jersey), and Devalingam Mahalingam, M.D., Ph.D. (Northwestern University), who will join the Oncolytics management team to discuss pelareorep's existing pancreatic clinical data in addition to its potential as an immunotherapy in mPDAC and other gastrointestinal indications. Oncolytics Biotech Inc
shares N.ONCY are trading off $0.05 at $1.14.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6519461854440610
